published meta-analysis   sensitivity analysis   studies

standard of care in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical deteriorationdetailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 0.27 [0.03; 2.68] 0.27[0.03; 2.68]ELACOI (lopinavir/ritonavir), 2020 (REV)10%28NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 2.06 [0.09; 47.98] 2.06[0.09; 47.98]ELACOI (lopinavir/ritonavir), 2020 (REV)10%25NAnot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 9.90 [0.48; 205.30] 9.90[0.48; 205.30]ELACOI (lopinavir/ritonavir), 2020 (REV)10%25NAnot evaluable viral clearance detailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 0.78 [0.11; 5.34] 0.78[0.11; 5.34]ELACOI (lopinavir/ritonavir), 2020 (REV)10%28NAnot evaluable viral clearance by day 14detailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 0.78 [0.11; 5.34] 0.78[0.11; 5.34]ELACOI (lopinavir/ritonavir), 2020 (REV)10%28NAnot evaluable viral clearance by day 7detailed resultsELACOI (lopinavir/ritonavir), 2020 (REV) 3.33 [0.52; 21.28] 3.33[0.52; 21.28]ELACOI (lopinavir/ritonavir), 2020 (REV)10%28NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:45 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 651 - roots T: 651